Leukine is a Intravenous; Subcutaneous Liquid in the Human Prescription Drug category. It is labeled and distributed by Sanofi-aventis U.s. Llc. The primary component is Sargramostim.
| Product ID | 0024-5844_ac281296-b49b-4f33-a16c-a83e60964713 |
| NDC | 0024-5844 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Leukine |
| Generic Name | Sargramostim |
| Dosage Form | Liquid |
| Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
| Marketing Start Date | 1996-12-01 |
| Marketing End Date | 2021-12-30 |
| Marketing Category | BLA / BLA |
| Application Number | BLA103362 |
| Labeler Name | sanofi-aventis U.S. LLC |
| Substance Name | SARGRAMOSTIM |
| Active Ingredient Strength | 500 ug/mL |
| Pharm Classes | Granulocyte Colony-Stimulating Factor [CS],Granulocyte-Macrophage Colony-Stimulating Factor [CS],Increased Myeloid Cell Production [PE],Leukocyte Growth Factor [EPC] |
| NDC Exclude Flag | N |
| Marketing Start Date | 1996-12-01 |
| Marketing End Date | 2021-12-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA103362 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1996-12-01 |
| Marketing End Date | 2021-12-30 |
| Marketing Category | BLA |
| Application Number | BLA103362 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1996-12-01 |
| Marketing End Date | 2021-12-30 |
| Ingredient | Strength |
|---|---|
| SARGRAMOSTIM | 500 ug/mL |
| SPL SET ID: | 04765fbf-f005-43aa-a628-5cc3d80f91e7 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0024-5843 | Leukine | SARGRAMOSTIM |
| 0024-5844 | Leukine | SARGRAMOSTIM |
| 71837-5843 | Leukine | SARGRAMOSTIM |
| 71837-5844 | Leukine | SARGRAMOSTIM |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() LEUKINE 73831918 1653426 Live/Registered |
IMMUNEX CORPORATION 1989-10-13 |